Steroidal MRA Across the Spectrum of Renal Function: A Pooled Analysis of RCTs.
Fiche publication
Date publication
novembre 2022
Journal
JACC. Heart failure
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick
Tous les auteurs :
Ferreira JP, Pitt B, McMurray JJV, Pocock SJ, Solomon SD, Pfeffer MA, Zannad F, Rossignol P
Lien Pubmed
Résumé
Mineralocorticoid receptor antagonists (MRAs) are underused in patients with kidney dysfunction, and their efficacy among patients with chronic kidney disease (CKD) is uncertain.
Mots clés
advanced chronic kidney disease, cardiorenal syndrome, heart failure, hyperkalemia, mineralocorticoid receptor antagonist
Référence
JACC Heart Fail. 2022 11;10(11):842-850